BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ADSTEM readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ADSTEM\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06893250-1277@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ADSTEM: Phase 2/3 readout est. (NCT06893250)
DESCRIPTION:ADSTEM\, phase 2/3.\nStudy: Orthobiologic Treatment for Knee Os
 teoarthritis\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adstem#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06893250
URL:https://assetmemo.bio/drug/adstem#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377838-1277@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:ADSTEM: Phase 3 readout est. (NCT07377838)
DESCRIPTION:ADSTEM\, phase 3\, Atopic Dermatitis.\nStudy: Study of ADSTEM I
 njection for Patients With Moderate to Severe Subacute and Chronic Atopic 
 Dermatitis\nEstimated primary completion: September 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/adstem#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07377838
URL:https://assetmemo.bio/drug/adstem#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
